GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE306nnn/GSE306038/primary200OKTranscriptomicsMus musculusExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306038GEOGSEfalseIntratumoral plasma cells are required for immune checkpoint blockade therapy in de novo MPNSTsIn most human cancers, intratumoral plasma cells connote improved patient survival and heightened anti-tumor response to immune checkpoint blockade (ICB) therapies, such as those targeting programmed death-ligand 1 (PD-L1) or programmed death 1 (PD1). Using an immunocompetent mouse model of de novo malignant peripheral nerve sheath tumors (MPNSTs), we found that plasma cells are required for successful anti-PD-L1 therapy and extended survival. In order to uncover the role of plasma cells in this response, we performed scRNA-seq of de novo MPNSTs within wild-type controls versus plasma cell-deficient AID-/-; µS-/- mice following CDK4/6-MEK inhibition. These results support our hypothesis that response to anti-PD-L1 is influenced by plasma cell infiltration into MPNSTs following CDK4/6-MEK inhibition.2026/08/19GSE306038GSM9191981GSM9191980GSM9191976GSM9191979GSM9191978GSM919197724247306038Mus musculus[42541926]